Clinical Scorecard: Molecular Pathways Involved in Cardiac Amyloidosis and Its Underlying Cardiovascular Pathology

At a Glance

Key Highlights

• CA is caused by transthyretin (ATTR) or immunoglobulin light chain (AL) amyloid deposition.
• Myocardial injury in CA reflects both fibril accumulation and soluble toxic intermediates.
• ATTR and AL differ in their upstream drivers and mechanisms of myocardial injury.
• Emerging evidence highlights the role of immune-inflammatory signaling in disease progression.
• Diagnosis is increasingly facilitated by advanced imaging and molecular testing.

Guideline-Based Recommendations

Diagnosis

• Utilize bone scintigraphy, cardiac magnetic resonance, and molecular diagnostic testing for accurate diagnosis.

Management

• Implement subtype-specific therapeutic strategies targeting both the initiating protein abnormality and downstream mechanisms.

Monitoring & Follow-up

• Regular assessment of cardiac function and symptoms in patients with CA.

Risks

• Increased risk of heart failure, arrhythmias, and progressive circulatory impairment.

Patient & Prescribing Data

Older adults, particularly men aged ≥70 years.

Management strategies should consider the specific subtype of CA (ATTR vs. AL) and associated clinical features.

Clinical Best Practices

• Early diagnosis through advanced imaging techniques.
• Consideration of both fibrillar deposition and soluble toxicity in treatment planning.
• Integration of immune-inflammatory factors into the understanding of disease progression.

Related Resources & Content

• Source Article